Respiree Raises Series A Extension

Respiree, a health tech company developing AI-powered platforms for managing disease progression, has expanded its Series A funding round. The company specializes in artificial intelligence platforms designed to manage disease progression across the healthcare continuum.

Investors

The round is led by We Venture Capital and ClavystBio. Additional participating investors include ARKRAY & PARTNERS Pte. Ltd., Bizedge Capital, Adaptive Capital Partners, Greenwillow Capital Management, Seeds Capital, and One Six 8 Ventures.

Respiree Use of Funds

Respiree plans to use the additional capital from this extended round to support the growth of its global commercial team and expand its presence in the United States, specifically through its operations at the Texas Medical Center Innovation in Houston.

About Respiree

Founded by CEO Dr. Gurpreet Singh, Respiree is an AI/ML health tech company developing clinically validated artificial intelligence solutions to manage disease progression across the healthcare continuum. Its 1Bio platform combines electronic health record data with proprietary, US-patented and FDA-cleared sensors to longitudinally measure and track disease progression. The company’s technology is available in the United States, Australia, and Asia-Pacific.

Funding Details

Company Website: https://respiree.com

Company: Respiree
Round: Series A Extension
Funding Date: September 2026
Lead Investor: We Venture Capital, ClavystBio
Additional Investors: ARKRAY & PARTNERS Pte. Ltd., Bizedge Capital, Adaptive Capital Partners, Greenwillow Capital Management, Seeds Capital, One Six 8 Ventures
Company Website: http://www.respiree.com
Software Category: Health Tech
Source: https://www.globenewswire.com/news-release/2026/09/22/3365926/0/en/respiree-extends-series-a-syndicate-with-addition-of-international-investors-to-support-continued-global-growth.html